AU2010202203B2 - Use of alpha-1- antitrypsin for the preparation of drugs for the treatment of chronic fatigue syndrome - Google Patents

Use of alpha-1- antitrypsin for the preparation of drugs for the treatment of chronic fatigue syndrome Download PDF

Info

Publication number
AU2010202203B2
AU2010202203B2 AU2010202203A AU2010202203A AU2010202203B2 AU 2010202203 B2 AU2010202203 B2 AU 2010202203B2 AU 2010202203 A AU2010202203 A AU 2010202203A AU 2010202203 A AU2010202203 A AU 2010202203A AU 2010202203 B2 AU2010202203 B2 AU 2010202203B2
Authority
AU
Australia
Prior art keywords
alpha
antitrypsin
aat
cfs
chronic fatigue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010202203A
Other languages
English (en)
Other versions
AU2010202203A1 (en
Inventor
Jose Alegre Martin
Ana Garcia Quintana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols SA
Original Assignee
Grifols SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols SA filed Critical Grifols SA
Publication of AU2010202203A1 publication Critical patent/AU2010202203A1/en
Application granted granted Critical
Publication of AU2010202203B2 publication Critical patent/AU2010202203B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2010202203A 2009-06-30 2010-05-28 Use of alpha-1- antitrypsin for the preparation of drugs for the treatment of chronic fatigue syndrome Active AU2010202203B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200930387 2009-06-30
ES200930387A ES2332645B1 (es) 2009-06-30 2009-06-30 Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica.

Publications (2)

Publication Number Publication Date
AU2010202203A1 AU2010202203A1 (en) 2011-01-20
AU2010202203B2 true AU2010202203B2 (en) 2012-08-23

Family

ID=41571181

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010202203A Active AU2010202203B2 (en) 2009-06-30 2010-05-28 Use of alpha-1- antitrypsin for the preparation of drugs for the treatment of chronic fatigue syndrome

Country Status (16)

Country Link
US (1) US9205134B2 (enExample)
EP (1) EP2289540B1 (enExample)
JP (1) JP5231490B2 (enExample)
CN (1) CN101934071B (enExample)
AR (1) AR077123A1 (enExample)
AU (1) AU2010202203B2 (enExample)
BR (1) BRPI1002087B1 (enExample)
CA (1) CA2706212C (enExample)
CL (1) CL2010000575A1 (enExample)
ES (2) ES2332645B1 (enExample)
MX (1) MX2010006125A (enExample)
NZ (1) NZ585890A (enExample)
PL (1) PL2289540T3 (enExample)
PT (1) PT2289540E (enExample)
RU (1) RU2436590C1 (enExample)
UY (1) UY32670A (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013096458A1 (en) * 2011-12-19 2013-06-27 Gtc Biotherapeutics, Inc. Recombinant human alpha-1-antitrypsin for the treatment of inflammatory disorders
WO2014140927A2 (en) 2013-02-13 2014-09-18 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
US20220160847A1 (en) * 2020-11-20 2022-05-26 Mark Egly Method of preventing and/or treating a plurality of diseases
WO2023184473A1 (zh) * 2022-04-01 2023-10-05 首创生物技术有限公司 肽用于治疗神经退行性疾病或改善认知功能的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019434A2 (en) * 2003-08-26 2005-03-03 The Regents Of The University Of Colorado, A Body Corporate Serine protease inhibitors for treatment of bacterial infections
WO2008143633A2 (en) * 2007-01-10 2008-11-27 University Of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2281222A (en) * 1941-09-27 1942-04-28 American Bosch Corp Speed regulator for internal combustion engines
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
DK0584185T3 (da) * 1991-05-14 2000-02-07 Ernir Snorrason Behandling af træthedssyndrom med cholinesteraseinhibitorer
WO2000051623A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
CN1554341A (zh) * 2000-04-21 2004-12-15 �������Ŷ���Լ��������˾ 用于治疗纤维肌痛和慢性疲劳综合症的化合物
US20040043510A1 (en) * 2000-07-14 2004-03-04 Nobuyuki Shigetoh Particle-labeled protein and immuno-chromatograph using the same
CA2506839A1 (en) 2002-11-20 2004-06-03 Arriva-Prometic Inc. Composition and method for treating inflammatory diseases using protease inhibitors
US7344882B2 (en) * 2003-05-12 2008-03-18 Bristol-Myers Squibb Company Polynucleotides encoding variants of the TRP channel family member, LTRPC3
WO2006026837A1 (en) * 2004-09-07 2006-03-16 Patrick Englebienne Diagnostic methods for measuring elastase activity levels
ES2281222B1 (es) * 2004-09-24 2008-06-01 Grifols, S.A. Utilizacion de alfa-1 antitripsina para la preparacion de medicamentos para el tratamiento de la fibromialgia.
EP2203051A4 (en) * 2007-09-25 2011-09-07 Abbott Lab OCTAHYDROPENTAL COMPOUNDS AS CHEMOKIN RECEPTOR ANTAGONISTS
CA2703393C (en) 2007-11-02 2018-07-24 Talecris Biotherapeutics, Inc. Method, composition, and article of manufacture for providing alpha-1 antitrypsin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019434A2 (en) * 2003-08-26 2005-03-03 The Regents Of The University Of Colorado, A Body Corporate Serine protease inhibitors for treatment of bacterial infections
WO2008143633A2 (en) * 2007-01-10 2008-11-27 University Of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency

Also Published As

Publication number Publication date
BRPI1002087B1 (pt) 2019-07-02
PT2289540E (pt) 2012-12-04
NZ585890A (en) 2011-11-25
BRPI1002087A2 (pt) 2012-03-13
EP2289540B1 (en) 2012-08-22
US20100331261A1 (en) 2010-12-30
MX2010006125A (es) 2011-01-05
HK1148198A1 (en) 2011-09-02
JP2011012060A (ja) 2011-01-20
UY32670A (es) 2011-01-31
ES2332645B1 (es) 2010-10-18
CL2010000575A1 (es) 2011-10-28
RU2436590C1 (ru) 2011-12-20
ES2332645A1 (es) 2010-02-09
CA2706212C (en) 2014-02-04
PL2289540T3 (pl) 2013-03-29
CN101934071A (zh) 2011-01-05
ES2392691T3 (es) 2012-12-12
AU2010202203A1 (en) 2011-01-20
CN101934071B (zh) 2012-11-28
JP5231490B2 (ja) 2013-07-10
EP2289540A1 (en) 2011-03-02
CA2706212A1 (en) 2010-12-30
AR077123A1 (es) 2011-08-03
US9205134B2 (en) 2015-12-08

Similar Documents

Publication Publication Date Title
US5418218A (en) Histidyl-proline diketopiperazine (cyclo his-pro) a cns-active pharmacologic agent
AU2010202203B2 (en) Use of alpha-1- antitrypsin for the preparation of drugs for the treatment of chronic fatigue syndrome
CN1711101A (zh) 孤独症及相似障碍的治疗
KR101401744B1 (ko) Ｎ-아세틸-ｌ-시스테인 또는 이의 유도체를 포함하는 불안 장애 치료용 약학 조성물
US20230026808A1 (en) Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
US9072737B2 (en) tPA mutant in the treatment of acute brain injury and neurodegenerative disorders
HK1148198B (en) Use of alpha-1-antitrypsin for the preparation of drugs for the treatment of chronic fatigue syndrome
AU2005203400B2 (en) Use of Alpha-1 antitrypsin for the preparation of medicaments for the treatment of fibromyalgia
CN115737781A (zh) 枸杞糖肽新用途及药物
Azuma et al. Improved response to infliximab after leukocytapheresis in a patent with rheumatoid arthritis
CN116139150A (zh) 小分子化合物lz-09在制备治疗和/或预防多发性硬化的药物中的应用
CA2698128A1 (en) Use of g-csf for the treatment of stroke
HK1083601B (en) Use of alpha-1 antitrypsin for the preparation of medicaments for the treatment of fibromyalgia

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ GARCIA QUINTANA, ANA; ALEGREMARTIN, JOSE .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ GARCIA QUINTANA, ANA AND ALEGRE MARTIN, JOSE